Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
  • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
  • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D223/08—Oxygen atoms
  • C07D223/10—Oxygen atoms attached in position 2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
  • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
  • A61P31/06—Antibacterial agents for tuberculosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
  • A61P31/22—Antivirals for DNA viruses for herpes viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
  • A61P33/06—Antimalarials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

• the invention relates to the use of 3-aminocaprolactam derivatives for preparing a medicament intended to prevent or treat inflammatory disorders.
• Inflammation is an important component of physiological host defence. Increasingly, however, it is clear that temporally or spatially inappropriate inflammatory responses play a part in a wide range of diseases, including those with an obvious leukocyte component (such as autoimmune diseases, asthma or atherosclerosis) but also in diseases that have not traditionally been considered to involve leukocytes (such as osteoporosis or Alzheimer's disease).
• leukocyte component such as autoimmune diseases, asthma or atherosclerosis
• diseases that have not traditionally been considered to involve leukocytes such as osteoporosis or Alzheimer's disease.
• the chemokines are a large family of signalling molecules with homology to interleukin- 8 which have been implicated in regulating leukocyte trafficking both in physiological and pathological conditions. With more than fifty ligands and twenty receptors involved in chemokine signalling, the system has the requisite information density to address leukocytes through the complex immune regulatory processes from the bone marrow, to the periphery, then back through secondary lymphoid organs.
• this complexity of the chemokine system has at first hindered pharmacological approaches to modulating inflammatory responses through chemokine receptor blockade. It has proved difficult to determine which chemokine receptor(s) should be inhibited to produce therapeutic benefit in a given inflammatory disease.
• BSCIs Broad Spectrum Chemokine Inhibitors
• peptides and peptoid derivatives such as NR58-3.14.3, may not be optimal for use in vivo. They are quite expensive to synthesise and have relatively unfavourable pharmacokinetic and pharmacodynamic properties.
• NR58-3.14.3 is not orally bioavailable and is cleared from blood plasma with a half-life period of less than 30 minutes after intravenous injection.
• Japanese patent application No. 09087331 describes 3-aminocaprolactam amide derivatives wherein the amide alkyl side chain may contain from 2 to 30 carbon atoms. These compounds have been presented as oil-gelating agents.
• the invention provides the use of a compound of general formula (I), or a pharmaceutically acceptable salt thereof, for the preparation of a medicament intended to treat inflammatory disorder:
• X is -CO-Y-(R 1 ) n or SO 2 -Y-(R 1 ),,;
• F: ⁇ Client Docs ⁇ SCRAS ⁇ 47746 ⁇ SPECS ⁇ 47746.WO01.Spec.doc Y is a cycloalkyl or polycyloalkyl group (such as an adamantyl, adamantanemethyl, bicyclooctyl, cyclohexyl, cyclopropyl group);
• each R 1 is independently selected from hydrogen or an alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl or alkylamino radical of 1 to 20 carbon atoms (for example of 5 to 20 carbon atoms, of 8 to 20 carbon atoms, of 9 to 20 carbon atoms, of 10 to 18 carbon atoms, of 12 to 18 carbon atoms, of 13 to 18 carbon atoms, of 14 to 18 carbon atoms, of 13 to 17 carbon atoms);
• each R 1 is independently selected from fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl or aminodialkyl radical;
• n is any integer from 1 to m, where m is the maximum number of substitutions permissible on the cyclo-group Y.
• R 1 may be selected from a peptido radical, for example having from 1 to 4 peptidic moieties linked together by peptide bonds (for example a peptido radical of 1 to 4 amino acid residues).
• the carbon atom at position 3 of the caprolactam ring is asymmetric and consequently, the compounds according to the present invention have two possible enantiomeric forms, that is, the "R” and “S” configurations.
• the present invention encompasses the two enantiomeric forms and all combinations of these forms, including the racemic "RS" mixtures. With a view to simplicity, when no specific configuration is shown in the structural formulae, it should be understood that the two enantiomeric forms and their mixtures are represented.
• the compounds of general formula (I) or pharmaceutically acceptable salts thereof used according to this aspect of the invention will be compounds of general formula (V)
• the compounds of general formula (I) or (I'), or their pharmaceutically acceptable salts will be such that the ring or rings of Y constrain the bond angles at the alpha-carbon to be essentially tetrahedral (i.e. sp3 hybrid bonds).
• the "alpha carbon” is either at the 2-position (relative to the amide carbonyl) or at the 1 -position (relative to the sulfonamide sulfonyl group).
• R 1 may be a substituent at any permissible position on the ring or rings of the cyclo-group Y.
• the invention includes compounds in which the "alpha carbon" is both part of the cyclo group and is itself substituted.
• compositions comprising, as active ingredient, a compound of general formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient and/or carrier:
• X is -CO-Y-(R 1 ) n or SO 2 -Y-(R 1 ) n ;
• Y is a cycloalkyl or polycyloalkyl group (such as an adamantyl, adamantanemethyl, bicyclooctyl, cyclohexyl, cyclopropyl group);
• each R 1 is independently selected from hydrogen or an alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl or alkylamino radical of 1 to 20 carbon atoms (for example of 5 to 20 carbon atoms, of 8 to 20 carbon atoms, of 9 to 20 carbon atoms, of 10 to 18
• each R 1 is independently selected from fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl or aminodialkyl radical;
• n is any integer from 1 to m, where m is the maximum number of substitutions permissible on the cyclo-group Y.
• R 1 may be selected from a peptido radical, for example having from 1 to 4 peptidic moieties linked together by peptide bonds (for example a peptido radical of 1 to 4 amino acid residues).
• the compounds of general formula (I) or pharmaceutically acceptable salts thereof used according to this aspect of the invention will be compounds of general formula (F)
• salt in particular the addition salts of inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, phosphate, diphosphate and nitrate or of organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulphonate, p-toluenesulphonate, palmoate and stearate.
• inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, phosphate, diphosphate and nitrate
• organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulphonate, p-toluenesulphonate, palmoate and stearate.
• bases such as sodium or potassium hydroxide.
• Salt selection for basic drugs Int. J. Pharm. (1986), 33, 201-217.
• the pharmaceutical composition can be in the form of a solid, for example powders, granules, tablets, gelatin capsules, liposomes or suppositories.
• Appropriate solid supports can be, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose,
• compositions according to the invention can also be presented in liquid form, for example, solutions, emulsions, suspensions or syrups.
• Appropriate liquid supports can be, for example, water, organic solvents such as glycerol or glycols, as well as their mixtures, in varying proportions, in water.
• the invention also provides compounds and salts thereof of general formula (I)
• X is -CO-Y-(R 1 ),, or SO 2 -Y-(R 1 ),,;
• Y is a cycloalkyl or polycyloalkyl group (such as an adamantyl, adamantanemethyl, bicyclooctyl, cyclohexyl, cyclopropyl group);
• each R 1 is independently selected from hydrogen or an alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl or alkylamino radical of 1 to 20 carbon atoms (for example of 5 to 20 carbon atoms, of 8 to 20 carbon atoms, of 9 to 20 carbon atoms, of 10 to 18 carbon atoms, of 12 to 18 carbon atoms, of 13 to 18 carbon atoms, of 14 to 18 carbon atoms, of 13 to 17 carbon atoms);
• each R 1 is independently selected from fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl or aminodialkyl radical;
• n is any integer from 1 to m, where m is the maximum number of substitutions permissible on the cyclo-group Y.
• R 1 may be selected from a peptido radical, for example having from 1 to 4 peptidic moieties linked together by peptide bonds (for example a peptido radical of 1 to 4 amino acid residues).
• the compounds of general formula (I) or salts thereof used according to this aspect of the invention will be compounds of general formula (F)
• the compounds of general formula (I) or (P) when used in the invention, or their salts will be such that the ring or rings of Y constrain the bond angles at the alpha- carbon to be essentially tetrahedral (i.e. sp3 hybrid bonds).
• preferred compounds of general formula (T) or (P) and their salts according to any aspect of the present invention are selected from the group consisting of:
• the most preferred compound is (iS)-3-(r-Adamantanecarbonyl)amino-caprolactam and salts thereof.
• the invention also provides the sulfonamide analogues of the exemplified compounds: i.e. the sulfonyl-amino-caprolactam equivalents of the said compounds.
• alkyl amide derivatives of 3- amino caprolactam may be known as compounds per se (though it is not presently known that any . have been described as such as pharmaceutical compositions or for medical use in an anti-inflammatory context).
• the invention includes compounds, compositions and uses thereof as defined, wherein the compound is in hydrated or solvated form.
• the amide derivatives of 3-aminocaprolactam described here are functional BSCIs. They are relatively inexpensive to synthesise, using facile synthesis routes provided herein; they are stable in human serum and consequently have excellent pharmacokinetic properties; they are orally bioavailable; they are highly potent broad-spectrum chemokine inhibitors in vitro with excellent selectivity over non-chemokine chemoattractants; they are highly potent and effective anti-inflammatory agents in vivo in rodent models of inflammation; their administration is not associated with any significant acute toxicity at the doses necessary to achieve a maximal therapeutic effect. Taken together, these properties suggest that amide derivatives of 3-aminocaprolactam represent anti ⁇ inflammatory medications with advantages over previously described compounds.
• the improvement of the present invention lies in the provision of the 3-aminocaprolactam moiety with a side chain having one or more alkyl/alkenyl rings to constrain the bond angles at the alpha carbon of the side chain.
• Compounds of this invention are significantly superior to compounds with linear alleyl chains (whether alkyl amides or alkyl sulfonamides).
• Prior art peptides (such as NR58-3.14.3) have the disadvantages that: (a) they are expensive and require solid phase synthesis (at least for the longer ones) and (b) they clear very quickly via the kidneys and (c) they are generally less potent.
• aminocaprolactams are cheap, not cleared by the kidney and even more potent, and are also metabolically stable.
• inflammatory disorders intended to be prevented or treated by the compounds of general formula (I) or (P) or the pharmaceutically acceptable salts thereof or pharmaceutical compositions or medicaments containing them as active ingredients include notably:
• autoimmune diseases for example such as multiple sclerosis
• vascular disorders including stroke, coronary artery diseases, myocardial infarction, unstable angina pectoris, atherosclerosis or vasculitis, e. g., Behcet's syndrome, giant cell arteritis, polymyalgia rheumatica, Wegener's granulomatosis, Churg- Strauss syndrome vasculitis, Henoch-Sch ⁇ nlein purpura and Kawasaki disease;
• viral infection or replication e.g. infections due to or replication of viruses including pox virus, herpes virus (e. g., Herpesvirus samiri), cytomegalovirus (CMV) or lentivirus;
• herpes virus e. g., Herpesvirus samiri
• CMV cytomegalovirus
• osteoporosis (low bone mineral density);
• organ transplant rejection and/or delayed graft or organ function e.g. in renal transplant patients
• disorders caused by intracellular parasites such as malaria or tuberculosis;
• inflammatory disorders include:
• fibrosis particularly pulmonary fibrosis, but not limited to fibrosis in the lung
• the invention also provides a method of treatment, amelioration or prophylaxis of the symptoms of an inflammatory disease (including an adverse inflammatory reaction to any agent) by the administration to a patient of an anti ⁇ inflammatory amount of a compound, composition or medicament as claimed herein.
• Administration of a medicament according to the invention can be carried out by topical, oral, parenteral route, by intramuscular injection, etc.
• the administration dose envisaged for a medicament according to the invention is comprised between 0.1 mg and 1O g depending on the type of active compound used.
• the compounds of general formula (I) or (F) can be prepared using the processes described hereafter.
• the reaction shown in Diagram 1 may be carried out, for example, in chloroform or dichloromethane.
• the most preferred reaction solvent is dichloromethane.
• the above reaction is preferably carried out in the presence of a base, for example Na 2 CO 3 .
• the above reaction may be carried out at ambient temperature (about 25 °C) or more generally at a temerature between 20 and 50 °C.
• compositions comprising as active ingredient a compound
• this terminology is intended to cover both compositions in which other active ingredients may be present and also compositions which consist only of one active ingredient as defined.
• peptidic moieties used herein is intended to include the following 20 naturally-occurring proteo genie amino acid residues:
• Figure 1 shows the chemical structure of examples of compounds according to the invention.
• 3-amino-caprolactam hydrochloride 2 (1 mmol) and Na 2 CO 3 (3 mmol) in water (15 ml) were added to a solution of 3,5-dimethyl-l-adamantanecarbonyl chloride (1 mmol) in dichloromethane (15 ml) at ambient temperature and the reaction was stirred for 12 hours. The organic layer was then separated and the aqueous phase was extracted with additional dichloromethane (2 x 25 ml). The combined organic layers were dried over Na 2 CO 3 and reduced in vacuo.
• the biological activity of the compounds of the current invention may be demonstrated using any of a broad range of functional assays of leukocyte migration in vitro, including but not limited to Boyden chamber and related transwell migration assays, under-agarose migration assays and direct visualisation chambers such as the Dunn Chamber.
• the 96-well format micro transwell assay system from Neuroprobe (Gaithersburg, MD, USA) has been used.
• this assay consists of two chambers separated by a porous membrane. The chemoattractant is placed in the lower compartment and the cells are placed in the upper compartment. After incubation for a period at 37°C the cells move towards the chemoattractant, and the number of cells in the lower compartment is proportional to the chemoattractant activity (relative to a series of controls).
• This assay can be used with a range of different leukocyte populations.
• leukocytes For example, freshly prepared human peripheral blood leukocytes may used.
• leukocyte subsets may be prepared, including polymorphonuclear cells or lymphocytes or monocytes using methods well known to those skilled in the art such as density gradient centrifugation or magnetic bead separations.
• immortal cell lines which have been extensively validated as models of human peripheral blood leukocytes may be
• the transwell migration systems are manufactured by Neuroprobe, Gaithersburg, MD,
• the plates used are ChemoTx plates (Neuroprobe 101-8) and 30 ⁇ l clear plates (Neuroprobe MP30).
• Geys' Balanced Salt Solution is purchased from Sigma (Sigma G-9779).
• Fatty acid-free BSA is purchased from Sigma (Sigma A-8806).
• MTT i.e. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
• Sigma Sigma (Sigma M-5655).
• RPMI-1640 without phenol red is purchased from Sigma (Sigma R-8755).
• the THP-I cell line (European Cell culture Collection) were used as the leukocyte cell population.
• the cell suspension to be placed in the upper compartment is prepared.
• the THP-I cells are pelleted by centrifugation (770 x g; 4 mins) and washed with Geys Balanced Salt Solution with lmg/ml BSA (GBSS + BSA). This wash is then repeated, and the cells repelleted before being resuspended in a small volume of GBSS + BSA for counting, for example using a standard haemocytometer.
• the volume of GBSS + BSA is then adjusted depending on the number of cells present so that the cells are at final density of 4.45 x 10 6 cells per ml of GBSS + BSA. This ensures that there are 100,000 THP-I cells in each 25 ⁇ l of the solution that will be placed in the upper chamber of the plate.
• MCP-I is diluted in GBSS + BSA to give a final concentration of 25 ng/ml. This is divided into two pots, as for the cell suspension. To one pot, the test compound is added to the same final concentration as was added to the cell suspension, while to the other pot an equal volume of GBSS + BSA plus vehicle as appropriate (e,g. not more than 1% DMSO) is added.
• vehicle e,g. not more than 1% DMSO
• the migration chamber should be assembled. Place 29 ⁇ l of the appropriate chemoattractant solution into the lower well of the chamber. Assays should be performed with at least triplicate determinations of each condition. Once all the lower chambers have been filled, apply the prous membrane to the chamber in accordance with the manufacturer's instructions. Finally, apply 25 ⁇ l of the appropriate cell solution to each upper chamber. A plastic lid is placed over the entire apparatus to prevent evaporation.
• the assembled chamber is incubated at 37 0 C, 5% CO 2 , for 2 hours.
• a suspension of cells in GBSS + BSA is also incubated under identical conditions in a tube: these cells will be used to construct a standard curve for determining the number of cells that have migrated to the lower chamber under each condition.
• the liquid cell suspension is gently removed from the upper chamber, and 20 ⁇ l of ice-cold 2OmM EDTA in PBS is added to the upper chamber, and the apparatus is incubated at 4°C for 15 mins. This procedure causes any cells adhering to the underside of the membrane to fall into the lower chamber.
• the number of cells migrated into the lower chamber under each condition can then be determined by a number of methods, including direct counting, labelling with fluorescent or radioactive markers or through the use of a vital dye.
• a vital dye MTT. 3 ⁇ l of stock MTT solution are added to each well, and then the plate is incubated at 37 0 C for 1-2 hours during which time dehydrogenase enzymes within the cells convert the soluble MTT to an insoluble blue formazan product that can be quantified spectrophotometrically.
• an 8-point standard curve is set up. Starting with the number of cells added to each upper chamber (100,000) and going down in 2-fold serial dilutions in GBSS + BSA, the cells are added to a plate in 25 ⁇ l, with 3 ⁇ l of MTT stock solution added. The standard curve plate is incubated along side the migration plate.
• the liquid is carefully removed from the lower chambers, taking care not to disturb the precipitated formazan product.
• 20 ⁇ l of DMSO is added to each lower chamber to solubilise the blue dye, and absorbance at 595nm is determined using a 96-well plate reader. The absorbance of each well is then interpolated to the standard curve to estimate the number of cells in each lower chamber.
• the MCP-I stimulated migration is determined by subtracting the average number of cells that reached the lower compartment in wells where no MCP-I was added from the average number of cells that reached the lower compartment where MCP-I was present at 25ng/ml.
• the impact of the test substance is calculated by comparing the MCP-I -induced migration which occurred in the presence or absence of various concentrations of the test substance.
• the inhibition of migration is expressed as a percentage of the total MCP-I induced migration which was blocked by the presence of the compound.
• a dose-response graph is constructed by determining the inhibition of MCP-I induced migration which occurs at a range of different compound concentrations (typically ranging from InM to l ⁇ M or higher in the case of poorly active compounds).
• the inhibitory activity of each compound is then expressed as the concentration of compound required to reduce the MCP-1-induced migration by 50% (the ED 50 concentration).
• the (S)- and (R)- enantiomers of two different members of the aminocaprolactarn series can be synthesised to determine whether the biological activity showed enantioselectivity.
• the dose-response curves for each of the compounds as inhibitors of MCP-I induced THP-I cell migration can be determined using the transwell migration assay.
• the compounds of the present invention as anti-inflammatory agents in vivo it is preferable to use the pure (S)-enantiomer of the compound, rather than the racemic mixture of the two enantiomers or the pure (R)-enantiomer.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Immunology (AREA)
• Physical Education & Sports Medicine (AREA)
• Epidemiology (AREA)
• Rheumatology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Neurology (AREA)
• Pulmonology (AREA)
• Virology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Cardiology (AREA)
• Oncology (AREA)
• Dermatology (AREA)
• Heart & Thoracic Surgery (AREA)
• Biomedical Technology (AREA)
• Communicable Diseases (AREA)
• Neurosurgery (AREA)
• Vascular Medicine (AREA)
• Pain & Pain Management (AREA)
• Biotechnology (AREA)
• Transplantation (AREA)
• Hospice & Palliative Care (AREA)
• Urology & Nephrology (AREA)
• Molecular Biology (AREA)
• Hematology (AREA)
• Diabetes (AREA)

Priority Applications (18)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=33017302

Family Applications (1)

Country Status (21)

Cited By (9)

Families Citing this family (2)

Citations (2)

Family Cites Families (17)

• 2004
  • 2004-08-11 GB GB0417863A patent/GB2418425B/en not_active Expired - Fee Related
• 2005
  • 2005-08-10 WO PCT/GB2005/003133 patent/WO2006016152A1/en not_active Ceased
  • 2005-08-10 BR BRPI0514250-4A patent/BRPI0514250A/pt not_active IP Right Cessation
  • 2005-08-10 AU AU2005271062A patent/AU2005271062B2/en not_active Revoked
  • 2005-08-10 JP JP2007525348A patent/JP4991540B2/ja not_active Expired - Lifetime
  • 2005-08-10 CN CN2005800301864A patent/CN101014347B/zh not_active Expired - Lifetime
  • 2005-08-10 DK DK05794153.6T patent/DK1781299T3/da active
  • 2005-08-10 US US11/573,637 patent/US7691845B2/en not_active Expired - Fee Related
  • 2005-08-10 RU RU2007104519/04A patent/RU2410376C2/ru not_active IP Right Cessation
  • 2005-08-10 PL PL05794153T patent/PL1781299T3/pl unknown
  • 2005-08-10 NZ NZ553718A patent/NZ553718A/en not_active IP Right Cessation
  • 2005-08-10 DE DE602005025493T patent/DE602005025493D1/de not_active Expired - Lifetime
  • 2005-08-10 CA CA2576257A patent/CA2576257C/en not_active Expired - Fee Related
  • 2005-08-10 AT AT05794153T patent/ATE492280T1/de active
  • 2005-08-10 MX MX2007001626A patent/MX2007001626A/es active IP Right Grant
  • 2005-08-10 EP EP05794153A patent/EP1781299B1/en not_active Revoked
  • 2005-08-10 ES ES05794153T patent/ES2357588T3/es not_active Expired - Lifetime
• 2007
  • 2007-01-29 ZA ZA200700827A patent/ZA200700827B/xx unknown
  • 2007-01-30 IL IL181055A patent/IL181055A/en not_active IP Right Cessation
  • 2007-02-15 KR KR1020077003701A patent/KR101341965B1/ko not_active Expired - Fee Related
  • 2007-03-12 NO NO20071321A patent/NO20071321L/no not_active Application Discontinuation
• 2010
  • 2010-03-17 US US12/726,311 patent/US8497261B2/en not_active Expired - Fee Related
  • 2010-10-15 RU RU2010142847/04A patent/RU2010142847A/ru not_active Application Discontinuation
• 2012
  • 2012-02-23 JP JP2012037773A patent/JP2012140444A/ja active Pending

Patent Citations (2)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events